Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
20.91 AUD | -9.52% | +0.92% | -16.30% |
May. 28 | Transcript : Neuren Pharmaceuticals Limited - Shareholder/Analyst Call | |
May. 27 | Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome | CI |
Sales 2024 * | 152M 101M | Sales 2025 * | 172M 115M | Capitalization | 2.95B 1.96B |
---|---|---|---|---|---|
Net income 2024 * | 91M 60.52M | Net income 2025 * | 99M 65.84M | EV / Sales 2024 * | 17.5 x |
Net cash position 2024 * | 289M 192M | Net cash position 2025 * | 398M 265M | EV / Sales 2025 * | 14.8 x |
P/E ratio 2024 * |
32.3
x | P/E ratio 2025 * |
30.1
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.53% |
Latest transcript on Neuren Pharmaceuticals Limited
1 day | -3.85% | ||
1 week | +7.29% | ||
Current month | +15.73% | ||
1 month | +15.43% | ||
3 months | +14.77% | ||
6 months | +47.74% | ||
Current year | -11.01% |
Managers | Title | Age | Since |
---|---|---|---|
Jon Pilcher
CEO | Chief Executive Officer | 58 | 13-08-18 |
Lauren Frazer
DFI | Director of Finance/CFO | - | 20-07-31 |
Liza Squires
CTO | Chief Tech/Sci/R&D Officer | - | 22-07-07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 02-03-04 | |
Dianne Angus
BRD | Director/Board Member | 63 | 18-07-04 |
Jenny Lee Harry
BRD | Director/Board Member | - | 18-07-04 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 746 M€ | -.--% | - | |
0.00% | 10 M€ | -3.35% | - | |
0.00% | 34 M€ | +4.49% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 20.91 | -9.52% | 449 322 |
24-05-28 | 23.11 | -3.59% | 985,075 |
24-05-27 | 23.97 | +15.74% | 1,182,630 |
24-05-22 | 20.71 | -0.10% | 263,091 |
24-05-21 | 20.73 | -1.33% | 297,723 |
Delayed Quote Australian S.E., May 28, 2024 at 09:19 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.01% | 2.04B | |
+38.59% | 727B | |
-7.89% | 354B | |
+15.66% | 328B | |
+0.24% | 277B | |
+13.47% | 243B | |
+7.35% | 205B | |
-6.42% | 203B | |
+4.23% | 164B | |
-1.70% | 164B |
- Stock Market
- Equities
- NEU Stock